Allergy Immunotherapy Market Research, 2033
The global Allergy Immunotherapy Market Size was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033. The allergy immunotherapy market growth is driven by a combination of rising prevalence of allergic disorders and advancements in treatment options. A key driver for this market is the increasing incidence of allergies worldwide. According to the World Health Organization estimates, 1 in 2 people in the world will be suffering from allergies diseases by 2050
Market Introduction and Definition
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment aimed at reducing the sensitivity to allergens. It involves the gradual introduction of increasing amounts of the allergen into the patient's body, typically through injections (subcutaneous immunotherapy) or sublingual tablets or drops (sublingual immunotherapy) . Over time, this process helps the immune system become less reactive to the allergen, thereby reducing the severity and frequency of allergic reactions. This therapy is primarily used to treat conditions such as allergic rhinitis, allergic asthma, and insect venom allergies. It is particularly beneficial for patients who do not respond well to conventional allergy medications.
Key Takeaways
- The allergy immunotherapy market share study covers 20 countries. The research includes a segment analysis of each country in terms of value ($Billion) for the projected 2024-2033 allergy immunotherapy market forecast period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major Allergy Immunotherapy industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global allergy immunotherapy marketand to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
The growing prevalence has driven the demand for effective long-term treatments, such as immunotherapy, which offers the potential for sustained relief and improvement in quality of life for allergy sufferers. Additionally, advancements in immunotherapy techniques, including sublingual immunotherapy (SLIT) and the development of more targeted and personalized therapies, are further propelling market growth by providing safer and more convenient options for patients.
However, the market faces significant restraints that could impede its expansion. One major challenge is the high cost of allergy immunotherapy treatments. The financial burden associated with these therapies can be prohibitive for many patients, especially those without comprehensive health insurance. Furthermore, the long duration of treatment, often spanning several years, can lead to non-adherence and dropout, reducing the overall effectiveness of the therapy. This cost barrier is exacerbated by the need for frequent visits to healthcare providers for injections or supervision, adding to the overall expense and inconvenience for patients.
Furthermore, one notable opportunity lies in the increasing adoption of digital health technologies and telemedicine. The integration of digital platforms for patient monitoring and remote consultations can enhance treatment adherence and accessibility, particularly in underserved regions. Moreover, ongoing research into novel allergens and the development of next-generation immunotherapies hold promise for more effective and tailored treatments. Collaborations between pharmaceutical companies and research institutions to explore innovative delivery methods, such as oral or intranasal immunotherapy, could further expand the market. Additionally, rising awareness and educational initiatives about the benefits of immunotherapy are likely to drive greater acceptance and uptake among patients and healthcare providers.
Prevalence of Self-Reported Allergies By Gender for Allergy Immunotherapy industry
According to an case study published in National Library Of Medicine in January 2022. The data shows the prevalence of self-reported allergies by gender, highlighting differences in allergy types for the allergy immunotherapy market. Women report higher overall allergy prevalence compared to men. Specific allergies like pollen (10.4% vs. 6.2%) , house dust mite (6.9% vs. 5.1%) , food (6.8% vs. 3.0%) , contact allergies (8.1% vs. 2.3%) , drug allergies (7.6% vs. 3.0%) , and animal allergies (7.6% vs. 3.0%) are more common in women. Insect venom and other allergies are also more frequent in women (4.4% and 1.6%) than in men (3.4% and 0.9%) . This indicates a significant gender disparity in allergy prevalence, which could impact the demand for allergy immunotherapy treatments.
Market Segmentation
The allergy immunotherapy market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into subcutaneous immunotherapy, and sublingual immunotherapy. On the basis of Application, the market is segmented into Allergy Rhinitis, Asthma, Food Allergy, and Others. On the basis of Distribution channels, the market is segmented into hospital pharmacies, retail, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional/Country Market Outlook
The Allergy Immunotherapy Market Size shows significant regional variation in its growth and adoption. North America, particularly the United States, dominates due to high prevalence of allergic conditions and advanced healthcare infrastructure. Europe, led by Germany and the UK, follows closely, supported by favorable reimbursement policies and extensive clinical research. In Asia-Pacific, countries like China and Japan are experiencing rapid market expansion, driven by increasing allergy awareness, improving healthcare access, and growing adoption of innovative therapies. Emerging markets in Latin America and the Middle East also show potential, with rising investments in healthcare and growing prevalence of allergies enhancing the demand for effective immunotherapy solutions.
- In June, 2021, Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France) . Alustal will be also available in Australia, France and Switzerland in the coming months.
- In November 2021, Vimian Group, signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany, a Canadian biotechnology company focused on the development of novel bioparticle-based vaccines.
Industry Trends
- In September 2023, Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT) , announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia.
- In February 2024, the U.S. FDA approved Xolair (omalizumab) injections for treating immunoglobulin E-mediated food allergies in specific adults and children. This medication reduces the risk of anaphylaxis from accidental food exposure.
Competitive Landscape
The major players operating in the Allergy Immunotherapy market share include Torii Pharmaceutical Co., Ltd., Biomay AG, ALK-Abello A/S, HAL Allergy Group, Allergy Therapeutics, Stallergenes Greer, Allovate LLC, Jubliant Pharma, Leti Pharma, and Merck KGaA. Other players in the Allergy Immunotherapy market include Zhejiang Wolwo Bio-pharmaceutical Co., Ltd, Holding Dermapharm, and so on.
Recent Key Strategies and Developments
- In April 2021, ALK-Abelló A/S, a pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products, initiated a clinical trial to study the safety and efficacy of sublingual immunotherapy tablets in children and adolescents suffering from allergic rhinitis induced by birch pollen.
- In October 2022, Allergy Partners, the nation’s largest single specialty allergy practice group leading the development and delivery of high-quality health care for patients with asthma and allergic disease, announced a strategic collaboration with Aimmune Therapeutics, Inc., a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal, and metabolic-related diseases, to provide Allergy Partners’ patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy with direct access to PALFORZIA, the first and only FDA-approved peanut allergy treatment.
Key Sources Referred
- World Health Organization (WHO)
- Centers for Medicare & Medicaid Services (CMS)
- World Allergy Organization
- National Health Service (NHS)
- National Health Mission (NHM)
- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration (FDA)
- National Institutes of Health (NIH)
- Mental Health Foundation
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergy immunotherapy market analysis from 2024 to 2033 to identify the prevailing allergy immunotherapy market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the allergy immunotherapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global allergy immunotherapy market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the allergy immunotherapy market players.
- The report includes the analysis of the regional as well as global allergy immunotherapy market trends, key players, market segments, application areas, and market growth strategies.
Allergy Immunotherapy Market, by Type Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 4.9 Billion |
 Growth Rate | CAGR of 10.4% |
 Forecast period | 2024 - 2033 |
 Report Pages | 216 |
 By Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Allovate, LLC, Jubliant Pharma, Merck KGaA, Allergy Therapeutics, Biomay AG, Stallergenes Greer, Torii Pharmaceutical Co., Ltd., ALK-Abello A/S, HAL Allergy Group, Leti Pharma |
The total market value of Allergy Immunotherapy Market is $1.8 billion in 2023.
The forecast period for Allergy Immunotherapy Market is 2024 to 2033
The market value of Allergy Immunotherapy Market in 2033 is $4.9 billion
The base year is 2023 in Allergy Immunotherapy Market .
Top companies such as Torii Pharmaceutical Co., Ltd., Biomay AG ,ALK-Abello A/S, HAL Allergy Group, Allergy Therapeutics, held a high market position in 2023. These key players held a high market postion owing to the strong geographical foothold in North America, Europe, Asia-Pacific, LAMEA.
The subcutaneous immunotherapy (SCIT) segment is the most influencing segment in Allergy Immunotherapy Market.
Loading Table Of Content...
